Methods and pharmaceutical compositions for the treatment of kidney cancer

US11052131B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• UNIVERSITÉ DE BORDEAUX · FR
• INSTITUT BERGONIE · FR

Inventors

• Géraldine SIEGFRIED · Blois, FR
• Abdel-Majid Khatib · Pessac, FR
• Jean-Luc Hoepffner · Bordeaux, FR
• Serge EVRARD · Bordeaux, FR

Key dates

• Filing date: Oct 4, 2017
• Grant date: Jul 6, 2021
• Expiry date: Oct 4, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/575
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are methods and pharmaceutical compositions for the treatment of kidney cancer. The inventors showed that while Elabela (ELA) is mostly expressed in kidney, its expression is reduced in human kidney cancer. In a xenograft animal model (sub-cutaneous, or sub-capsular injection) Ela inhibits tumor progression. In particular, there is disclosed a method of treating kidney cancer in a subject in need thereof including administering to the subject a therapeutically effective amount of an ELA polypeptide including an amino acid sequence having at least 90% of identity with SEQ ID NO: 1 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP) wherein the arginine residue (R) at position 9, 10, 20 or 21 is optionally mutated.